A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis

• Status: Completed
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Corticosteroids are one of the mainstays of treatment for subjects with corticosteroid-responsive dermatoses such as psoriasis. This study has been designed to determine and compare the efficacy and safety of a formulation of 122-0551 versus the corresponding Vehicle in subjects with stable plaque psoriasis after twice daily dosing for 14 consecutive days.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Therapeutics, Inc.

Criteria

Inclusion Criteria:

• Subject has a clinical diagnosis of stable plaque psoriasis

• Subject has an ODS score for the Treatment Area of 3 or 4 at study start

Exclusion Criteria:

• Subject has spontaneously improving or rapidly deteriorating plaque psoriasis.

• Subject has guttate, pustular, erythrodermic or other non-plaque forms of psoriasis.

• Subject has used any phototherapy, photo-chemotherapy or systemic corticosteroid therapy within 30 days prior to study start

• Subject has used any systemic methotrexate, retinoids, cyclosporine or analogous products within 90 days prior to study start

• Subject has used any systemic biologic therapy for the treatment of psoriasis within 5 half-lives of the biologic prior to study start

• Subject had prolonged exposure to natural or artificial sources of ultraviolet radiation within 30 days prior to study start

• Subject has used topical body (excluding the scalp) psoriasis therapy including coal tar, anthralin, steroids, retinoids, vitamin D analogs (e.g., Dovonex®) within 14 days prior to study start

• Subject has used emollients/moisturizers on areas to be treated within four hours prior to clinical evaluation at study start

• Subject is currently using lithium or Plaquenil (hydroxychloroquine)

• Subject is currently using a beta-blocking medication (e.g., propranolol) or ACE (e.g., lisinopril) inhibitor at a dose that has not been stabilized

• Subject is pregnant, lactating, or is planning to become pregnant during the study

• Subject is currently enrolled in an investigational drug or device study

• Subject has used an investigational drug or investigational device treatment within 30 days prior to study start

• Subject has been previously enrolled in this study and treated with a test article